anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a one group pretest- posttest design conducted in all patients presenting in Chest clinic of Dhulikhel Hospital-Kathmandu University Hospital, Nepal from March 2017 to May 2017. Patients diagnosed of having COPD, Asthma or Asthma-COPD Overlap Syndrome (ACOS) and were under inhalation bronchodilators in the form of Dry Powder Device via Rotahaler were included. Enrolled patients are assessed for inhalation technique compliance at their routine medical (pre-training) visits by physician. The use of inhaler device is evaluated in a practical manner by asking the patients to demonstrate their inhalation technique. After the assessment, instructions and training are given until they can use the device correctly. One month later (post-training), all patients are re-evaluated in regards to inhalation technique and subjective improvement of symptoms.
The present invention provides novel methods for producing human monoclonal antibodies capable of binding an epitope on gram negative bacterial core lipopolysaccharide comprising the steps of (1) screening monoclonal antibodies secreted from transformed human cell lines by employing a competitive assay against non-human monoclonal antibodies capable of binding such an epitope and (2) selecting human cell lines which secrete monoclonal antibodies competitive with the non-human monoclonal antibodies. The present invention further contemplates monoclonal antibodies produced by those methods and the hybridoma cell lines producing such monoclonal antibodies. Preferably the human cell lines are derived from human B lymphocytes from a person hosting an infection of gram negative bacteria and are transformed with Epstein-Barr virus. Most preferably the Epstein-Barr virus is that released by B95-8 marmoset lymphoma cells having A.T.C.C. Accession No CRL 1612 and the non-human hybridoma cell line is selected from the group consisting of the cell lines designated A.T.C.C. Accession Nos HB 9081, HB 9082, HB 9083 and HB 8909. The monoclonal antibodies produced by the cell lines of the present invention are useful in the detection of bacterial infections, therapy and prophylaxis of bacterial endotoxemia and infection caused by gram negative bacteria.
PURPOSE OF REVIEW: Frailty is prevalent in older adults with cancer and can lead to complications during cancer treatment and poor health outcomes. Exercise has been shown to be a promising strategy to mitigate frailty and slow the accumulation of functional impairment in the general geriatric population. In this review, we present a discussion on the state of the science of exercise interventions for frail older adults with cancer. This review is timely and relevant given the aging of the population and corresponding increase in proportion of older adults living with cancer.
RECENT FINDINGS: Existing research related to exercise interventions for frail older adults with cancer appear to show some promise in feasibility and efficacy in both surgical and systemic treatment settings.
SUMMARY: More research on this topic and testing rigorously structured exercise interventions for older adults with cancer may help inform cancer-specific guidelines and create a foundation of evidence to enable implementation of exercise interventions. These interventions can support cancer care to attenuate frailty-related outcomes while extending its benefit to overall health of this population.
FIELD: medicinal sealing materials. SUBSTANCE: fibrin sealer, in particular, thrombin-free composition containing fibrin monomer or composition containing non-cross-linking fibrin is applied by bringing it into contact with required area. In this procedure, fibrin monomer converts into fibrin polymer thereby manifesting sealing effect. Thrombin-free aqueous composition containing non-cross-linking fibrin is used in concentration 10 to 200 mg/ml. EFFECT: avoided risk of viral infection or other adverse effects. 70 cl, 1 dwg, 2 tbl
<P>PROBLEM TO BE SOLVED: To provide transgenic animals producing humanized monoclonal antibodies and humanized monoclonal antibodies produced therefrom.  <P>SOLUTION: They are transgenic non-human animals operated so as to contain human immunoglobulin gene loci. In particular, animals in accordance with the invention possess human Ig gene loci that include a plurality of variable (VH and Vκ) genes regions. Advantageously, the inclusion of a plurality of variable region genes enhances the specificity and diversity of human antibodies produced by the animal. Further, the inclusion of such regions enhances and reconstitutes B-cell development to the animals, such that the animals possess abundant mature B-cells secreting extremely high affinity antibodies.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The morphology of the soft tissue around the teeth (buccolingual GT and keratinized gingival width) is defined as the "gingival phenotype". One of the most important considerations when assessing gingival phenotype is the objective quantification of GT, and various methods have been used to measure GT. However, there is no clear consensus in the literature regarding the anatomical point where GT is measured in the buccal region. For this reason, it is thought that measurements made from different points also affect the classification of gingival phenotype. The aim of this study was to investigate the cut-off values in clinical parameters according to the average GT value of different measurement points and the GT value at a single point.

The study was designed as cross-sectional study. Participants were divided into two groups based on thin and thick gingival phenotypes in two different classifications. The first classification was based on the GT measurement taken from the base of the gingival sulcus, while the second classification was based on the average of GT measurements taken from three points (base of the gingival sulcus, 1 mm apical to the base of the gingival sulcus, and 2 mm apical to the base of the gingival sulcus. Other clinical and morphological parameters of the participants, who were divided into two groups (thin and thick) according to these classifications, were also measured with a digital caliper and periodontal probe. These parameters are keratinized gingival width (KGW), gingival groove depth (SD), crown width (CW), crown length (CL), crown width/crown length (CW/CL), papilla height (PH), gingival angle (GA). is. Among these parameters, the unit of measurement for GA is angle. CW/CL is the ratio. Other measurements were measured in mm. For all parameters, cut-off values were obtained through statistical measurements made according to two classifications. And these measurements were compared. In addition, the compatibility of the GT measurements of the three points with each other was also examined.

Participants Ondokuz Mayis University's Clinical Research Ethics Board approved the consent form and study protocol (210/2021). Participants with 1195 teeth sites, were enrolled in the study from September 2022 to August 2023. Participants were recruited from University Ondokuz Mayis included patients, dental/ hygiene students. A single calibrated examiner (SY) performed all clinical and morphological measurements.
Type 2 diabetes is an up rising disease that makes it a major public health problem. While 221 millions cases were estimated in 2010, the prevalence would be 366 millions in 2030. It is well recognized that regular consumption of fruits and vegetables can lower the incidence of chronic diseases such as cancer, cardiovascular diseases, diabetes and inflammatory diseases. Recently, Drs Desjardins, Abrams and Marette's research team discovered a high amount of a sesquiterpene in berries. This molecule is recognized for its ability to improve glucose tolerance and insulin sensitivity, and to lower pro-inflammatory profile of obese mice. The aim of this study is to determine the effect of a polyphenol rich berries extract mix on insulin sensitivity, glucose tolerance, pancreatic β-cells function, lipids and inflammatory profile, and oxidative stress markers, on human obese subjects that have insulin resistance.
Dexmedetomidine (Precedex, Meditera, USA) was administered at a loading dose of 1 µg/kg for 10 minutes before local anesthesia to be applied to the eye by the surgeon. During the surgical procedure, it was administered at a dose of 0.4 µg/kg/h-1 infusion.
OBJECTIVE: This study aims to investigate independent factors associated with 30-day mortality in patients with acute spontaneous intracerebral hemorrhage (SICH) before treatment.
METHODS: A retrospective analysis was performed on medical records of patients hospitalized with acute SICH between 2019 and 2021. Data included personal history, hospital stay duration, symptom onset, chief complaint, underlying diseases, medication, and alcohol/smoking habits. Physical examination records comprised baseline blood pressure, Glasgow Coma Scale assessment, and pupil reaction evaluation. Diagnostic imaging, specifically computed tomography brain scans, was examined for hemorrhage details. Multivariable logistic analysis was utilized for data analysis.
RESULTS: Among 663 cases, 185 (27.9%) experienced mortality. Risk factors for mortality included chronic kidney disease, ischemic heart disease, loss of follow-up in hypertension clinic, and pontine hemorrhage. Conversely, motor response (m), reactive pupils, and basal cistern persistence significantly decreased the risk of mortality in multivariable analysis. Receiver operating characteristic analysis identified a m score of 5 as the cutoff for predicting survival.
CONCLUSIONS: Chronic kidney disease, ischemic heart disease, loss of hypertension follow-up, m, reactive pupils, pontine hemorrhage, and basal cistern persistence were independent variables associated with the 30-day mortality rate in SICH patients before treatment initiation. A m, pupil reaction, and basal cistern persistence serve as predictive tools for assessing mortality in SICH before treatment.
PROBLEM TO BE SOLVED: To provide topical and oral delivery dosage forms of a composition comprising one or more active agents, for treating a disease or symptoms in a subject.SOLUTION: The present invention provides a composition comprising at least one active compound, e.g., finasteride or minoxidil, and one or more lipids. The present invention also provides a composition and a method of preparation thereof, for treating androgenic alopecia (AGA), preventing hair loss and for female hirsutism. The composition comprises finasteride and at least one lipid component for the treatment of benign prostatic hyperplasia. The present invention provides a preparation method of a composition comprising at least one active compound and at least one lipid, for the treatment of skin or eye related diseases, wherein tacrolimus or amphotericin B and at least one lipid component are comprised. Further, the present invention provides administration of the composition to a subject by oral or topical delivery. The subject is a mammal. The subject is a human.SELECTED DRAWING: None
The prevalence of posttraumatic olfactory dysfunction in children after mild traumatic brain injury ranges from 3 to 58%, with potential factors influencing this variation, including traumatic brain injury severity and assessment methods. This prospective longitudinal study examines the association between mild traumatic brain injury and olfactory dysfunction in children. Seventy-five pediatric patients with mild traumatic brain injury and an age-matched healthy control group were enrolled. Olfactory function was assessed using the Sniffin' Sticks battery, which focuses on olfactory threshold and odor identification. The study found that children with mild traumatic brain injury had impaired olfactory function compared with healthy controls, particularly in olfactory threshold scores. The prevalence of olfactory dysfunction in the patient group was 33% and persisted for 1 yr. No significant association was found between traumatic brain injury symptoms (e.g. amnesia, loss of consciousness) and olfactory dysfunction. The study highlights the importance of assessing olfactory function in children after mild traumatic brain injury, given its potential impact on daily life. Although most olfactory dysfunction appears transient, long-term follow-up is essential to fully understand the recovery process. The findings add valuable insights to the limited literature on this topic and urge the inclusion of olfactory assessments in the management of pediatric mild traumatic brain injury.
The present invention relates to technical field of Chinese medicine, more particularly to a kind of Chinese medicine composition with uric acid resisting effect and its preparation method and application.The Chinese medicine composition is made up of Rhizoma Smilacis Glabrae, Rhizoma Corydalis, Gynura procumbens (Lour.) Merr. and Herba Hordei Vulgariss.Through scientific composition, after Rhizoma Smilacis Glabrae, Rhizoma Corydalis, Gynura procumbens (Lour.) Merr. and Herba Hordei Vulgariss are applied in combination, with significant uric acid resisting effect, its uric acid resisting effect is better than effect that Rhizoma Smilacis Glabrae, Gynura procumbens (Lour.) Merr. or Herba Hordei Vulgariss are used alone to the present invention, can be used to treat gout.Clinical test results show Chinese medicine preparation total effective rate of the present invention up to 98%.
Use of PRADAII regimen during 12 weeks. This regimen consists of atazanavir 400 mg QD, dolutegravir 50 mg QD, lamivudine 300 mg QD.
Participants will receive metformin 850 mg PO once a day for 2 weeks. After 2 weeks, participants will receive metformin 1700 mg PO once a day for the remaining 10 weeks.
INTRODUCTION: The recovery of cerebrovascular disease (CVD) will increase the incidence of perioperative pneumonia (POP). However, there is limited research on POP in elderly patients with hip fractures complicated by CVD. Therefore, our research focuses on the following two issues: (1) What are the clinical features of elderly patients with hip fractures combined with CVD? (2) What are the predictive factors for the occurrence of POP in such patients?
HYPOTHESIS: Male, femoral neck fracture and hypoalbuminemia can be predictive factors for the development of POP after hip fracture in CVD patients.
MATERIAL AND METHODS: This is a nested case-control study that included patients aged 65 to 105 years with CVD who had a hip fracture between January 2021 and January 2023. According to the occurrence of POP, they were divided into case group and control group. Collecting data includes demographic information, clinical data, and surgical information. Least absolute shrinkage and selection operator (LASSO) regression and multivariate logistic regression analyses were used to select variables. The constructed predictive model was transformed into a nomogram. Predictive performance was assessed using the area under the receiver operating characteristic curve (AUC), calibration curves and decision curve analysis (DCA).
RESULTS: We ultimately included 714 patients, 69.3% female, with a median age of 80 years. Asymptomatic cerebral infarction (ACI) is the most common CVD (55.7%). More patients developed intertrochanteric fractures than femoral neck fractures (57.1 vs. 42.9%). In total, 606 patients (84.9%) underwent surgery. The most common perioperative complications were anemia (76.9%) and hypoalbuminemia (71.8%). POP (20.0%) was more common preoperatively (89.5%). Factors such as fracture type, surgical wait time, implant used for surgery, and anesthesia type did not differ between the presence or absence of postoperative pneumonia. 143 patients with POP served as the case group. Five hundred and seventy one patients did not develop POP and served as the control group. The predictors of POP were male (OR 1.699,95%CI 1.150-2.511, p<0.05), femoral neck fracture (OR 2.182,95%CI 1.491-3.192, p<0.05), and hypoalbuminemia (OR 3.062, 95%CI 1.833-5.116, p<0.05). This model has good discrimination, calibration, and clinical practicality.
DISCUSSION: In this study, we constructed a clinical prediction model for the occurrence of POP in CVD combined with hip fracture in the elderly, with risk factors including gender, fracture type and perioperative hypoproteinemia. Therefore, we can take effective preventive measures against the occurrence of POP in patients with these factors in our clinical work.
LEVEL OF PROOF: IV; nested case-control study.
PURPOSE:To obtain an antitumor agent comprising a ruthenium complex as an active ingredient. CONSTITUTION:This antitumor agent comprises a ruthenium complex of the formula [X is SR, SeR, TeR or halogen (R is alkyl, cycloalkyl, etc.; L is pentamethylcyclopentadienyl, indenyl, pyrazolyl borate, etc.; Z<-> is inorganic acid ion or organic acid ion] as an active ingredient. The agent can be pharmaceutically manufactured into a dosage form such as injection, suppository, tablet, capsule, granule, powder, etc. Generally 0.1-99.5 w/w % of the ruthenium complex is added. A daily dose is 0.1-100mg/kg. The agent is effective for human and mammal cancer such as hepatoma, lung cancer, stomach cancer, colon cancer, sarcoma such as malignant melanoma or fibrosarcoma and leukemia.
Patients undergo near margin-less ART for 2 treatments at least 3 days apart in the absence of disease progression or unacceptable toxicity. Patients also undergo CBCT and may undergo CT and/or MRI on study.
A material (A) containing an allergen (I) subjected to antiallergenic pretreatment is claimed for use as a medicament for specific immunotherapy. An independent claim is included for use of (A) in the production of a medicament for specific immunotherapy. ACTIVITY : Antiallergic. MECHANISM OF ACTION : Specific immunotherapy. In double-blind, placebo-controlled oral provocation tests, a 25-year old male patient with an allergy to consumption of apples was given 1 g of native apple (golden delicious variety) or 50 g of apple previously subjected to a hydrostatic ultra-high pressure of 600 MPa for 5 minutes. Treatment with the pretreated apple caused no symptoms of allergic reaction, increased the interleukin 10 mRNA level and increased tolerance. In vitro analysis also demonstrated reduced binding of the IgE of the patient to the isolated allergen.
A compound, process and method for increasing external auditory canal patency while simultaneously preventing the occurrence of otitis externa is disclosed wherein an aerosolized mixture of lipid crystals comprised of a mixture of one or more lipids surfactants and one or more spreading agents selected from the group consisting of sterols, lipids, fatty acids, cholesteryl esters, phospholipids, carbohydrates, nucleic acids and proteins, in powder form, and one or more fluorocarbon propellants is administered directly to the external auditory canal. Upon administration, the propellant(s) are evaporated from the mixture and the lipid crystals are deposited upon an air/liquid interface resident upon epithelial tissue lining the external auditory canal. Upon contact of said lipid crystals with the epithelial lining, an amorphous spread film is formed thereupon so as to form a barrier against exogenous water while simultaneously and substantially decreasing the surface tension of said lining so as to increase the patency thereof. In a second preferred embodiment, a therapeutically active agent effective in the treatment of otitis externa is added to the mixture of lipid crystals and upon administration of said aerosol mixture, the amorphous spread film formed thereby carries said therapeutically active agent throughout the epithelium of the outer ear canal so as to improve the patency thereof by both reducing surface tension of said epithelial lining and by efficiently treating the inflammatory process. In an alternate preferred embodiment, the afore-mentioned reduction of surface tension and delivery of therapeutically active agents is provided by a mixture of lipid crystals comprised of surfactant(s), therapeutically active agents and a propellant in which such other components are not soluble. In an alternate preferred embodiment, the afore-mentioned reduction of surface tension and delivery of therapeutically active agents is provided by a mixture of lipid crystals comprised of surfactant(s), therapeutically active agents and a propellant in which such other components are not soluble.
OBJECTIVE: The purpose of this study was to examine the longitudinal changes in trunk acceleration, gait speed, and paretic leg motion in patients with post-stroke hemiparesis, the relationships between variables at each time point, and whether initial trunk acceleration and gait parameters were related to gait speed 2 months later.
METHODS: Gait was assessed monthly in patients who could walk under supervision after stroke onset. Gait parameters, including gait speed and trailing limb angle (TLA), were measured. Trunk acceleration was quantified using acceleration root mean square (RMS) and stride regularity (SR) indices.
RESULTS: This study found statistically significant longitudinal changes in gait speed (p < .001), acceleration RMS of the total axes (p < .001), and SR of the vertical axes (p < .001). Gait speed correlated significantly with the acceleration RMS of the mediolateral (r = -0.815 to -0.901), vertical (r = -0.541 to -0.747), and anteroposterior (r = -0.718 to -0.829) axes, as well as the SR of the vertical axes (r = 0.558 to 0.724) at all time points from T0 to T2. For the TLA, only the acceleration RMS of the mediolateral axis correlated significantly over the entire study period (r = -0.530 to -0.724). In addition, initial TLA correlated significantly with gait speed after 2 months (r = -0.572).
CONCLUSION: This study showed that assessing trunk acceleration helps estimate the improvement in gait status in patients with post-stroke hemiparesis. The magnitude and regularity of trunk acceleration varied longitudinally and were related to gait speed and paretic leg motion at each time point; however, they could not predict future changes in gait speed.
Motor vehicle crashes are the leading cause of death for people aged 13-25 years in the US, and approximately 31% of all fatal crashes involved some alcohol use. Several peer-reviewed studies have found that ridesharing was associated with fewer alcohol-involved crashes and DUI arrests. Theories of behavioral economics provide a clear theoretical mechanism by which ridesharing will reduce alcohol-involved motor vehicle crashes compared to other private transportation. However, while ridesharing may be an effective intervention to reduce alcohol-involved crashes, it may simultaneously increase alcohol consumption. This study will assess the impacts of subsidized ridesharing on impaired driving, alcohol consumption, and mobility. Participants will be randomized to either receive a rideshare voucher or an online shopping voucher, and effects on alcohol impaired driving and alcohol consumption will be measured. A GPS sub-group will use a custom smartphone application for GPS tracking to measure mobility.
Presently, there are many drugs for the treatment of atherosclerosis (AS), among which lipid-lowering, anti-inflammatory, and antiproliferative drugs have been the most studied. These drugs have been shown to have inhibitory effects on the development of AS. Nanoparticles are suitable for AS treatment research due to their fine-tunable and modifiable properties. Compared with drug monotherapy, experimental results have proven that the effects of nanoparticle-encapsulated drugs are significantly enhanced. In addition to nanoparticles containing a single drug, there have been many studies on collaborative drug treatment, collaborative physical treatment (ultrasound, near-infrared lasers, and external magnetic field), and the integration of diagnosis and treatment. This review provides an introduction to the therapeutic effects of nanoparticles loaded with drugs to treat AS and summarizes their advantages, including increased targeting ability, sustained drug release, improved bioavailability, reduced toxicity, and inhibition of plaque and vascular stenosis.